AbbVie Inc.

- AbbVie expects adjusted net interest expense of $2 billion in 2024 to finance the ImmunoGen and Cerevel transactions, indicating use of debt financing for acquisitions. - The company notes $0.42 of earnings per share dilution related to recent ImmunoGen acquisition and pending Cerevel acquisition, implying equity impact though no explicit equity fundraising mentioned. - No specific new fundraising plans through debt or equity beyond the above are discussed in the transcript. - AbbVie emphasizes strong financial position and solid earnings growth despite acquisition-related expenses. In summary, AbbVie is currently financing recent and pending acquisitions partly through increased debt (net interest expense guidance), with no explicit mention of new fundraising rounds via equity or additional debt beyond this context.

- AbbVie recently completed the acquisition of ImmunoGen, accelerating entry into the solid tumor market and strengthening oncology pipeline. - Integration with ImmunoGen has been seamless, adding high-caliber talent to AbbVie. - On track to close the pending acquisition of Cerevel by mid-2024, which will augment AbbVie's neuroscience portfolio. - Continuing to advance long-term growth through development opportunities and partnerships in oncology and immunology. - Focused on investing in aesthetics, especially as the China market recovers, with plans to invest in consumer activation and launch new products to support this growth. - No specific dollar amounts for capital expenditures were disclosed, but strategic investments are clearly focused on acquisitions and pipeline expansion to support long-term growth.

- AbbVie expects robust revenue growth in 2025, accelerating further in 2026 and beyond, driven by expanding margins post-Part D benefit redesign (Page 6). - The ex-Humira growth platform delivered over 15% revenue growth in Q1 2024, indicating strong momentum (Page 1). - Continued strong growth anticipated in products like Skyrizi and Rinvoq, especially with favorable access and market penetration (Pages 4, 6). - The aesthetics business sees a seasonal pickup in H2 2024 after headwinds in China, indicating recovery and continued investment in growth (Page 8). - The oncology pipeline is strengthened by recent acquisitions and approvals (e.g., Elahere), supporting long-term growth (Page 1). - Humira U.S. volume declines are aligned with expectations, but broader segment growth and new patient starts on biosimilars/better treatments support overall revenue growth (Pages 6, 8). - Contracting strategies focus on multi-year contracts to maintain access and stable revenue streams (Page 4).

- Robust revenue growth expected in 2025, with acceleration in 2026 and beyond (Rob Michael). - Operating margin anticipated to expand, generally leading to earnings growth outpacing revenue growth. - Exception in 2025 due to dynamic net interest expense impacting earnings growth rate, but still solid earnings growth projected. - AbbVie raised 2024 adjusted EPS guidance by $0.16 to between $11.13 and $11.33, reflecting strong start and momentum. - Long-term outlook: high-single-digit revenue CAGR through end of decade, supporting strong EPS growth. - Earnings growth supported by diversified portfolio, strong ex-Humira growth, plus new product launches and acquisitions (e.g., ImmunoGen, Cerevel). - Continued margin expansion and operational leverage expected as pipeline and commercial execution support profitability gains.

The transcript provided from the PDF file does not include any specific information regarding the current or expected orderbook or pending orders. The discussion primarily revolves around: - Pricing dynamics and volume impacts related to Humira, including formulary changes and CVS contract effects. - Competitive positioning and market share insights for various AbbVie products like Qulipta, Botox, Skyrizi, Rinvoq, and Elahere. - Contracting strategies with payers emphasizing parity contracts and multi-year agreements for sustained relationships. - Market outlooks for aesthetics, particularly in China, with mention of economic headwinds and inventory impacts. - Financial details like cash payments for royalties and sales figures of recent acquisitions. There is no direct mention of orderbook statuses or pending orders in the excerpts on these pages.